

BLMK AREA PRESCRIBING COMMITTEE ANNUAL REPORT April 2024 to March 2025



“To promote rational, evidence-based, high quality, cost-effective medicines optimisation across Bedfordshire, Luton and Milton Keynes in order to ensure equity of access to medicines for all residents.”

The following organisations contribute to and participate in the BLMK Area Prescribing Committee – Bedfordshire, Luton and Milton Keynes Integrated Care Board; Bedfordshire Hospitals NHS Foundation Trust; Cambridgeshire Community Services NHS Trust; Central and North West London NHS Foundation Trust; East London NHS Foundation Trust; Milton Keynes University Hospital NHS Foundation Trust

© NHS BLMK ICB June 2025

Contents

Introduction	3
APC Subgroups	4
Participating Organisations	5
Meeting Attendance Figures	5
Committee Activities and Achievements	7
Communication and consultation	7
Guidelines, Pathways and Bulletins	7
Shared care guidelines/Information for GPs	8
Miscellaneous Documents.....	8
NICE Guidance	9
Reports received from Subgroups.....	9
APC Newsletter	10
Future Work Programme	10
Summary	11
Appendix 1: Output from the BLMK Area Prescribing Committee meetings held between April 2024 and March 2025.....	12
Appendix 2: Assessment against Ethical and Commissioning Principles	13
Appendix 3: NICE Technology Appraisal Guidance (ICB Commissioned)	15

BLMK AREA PRESCRIBING COMMITTEE (APC) ANNUAL REPORT

April 2024 to March 2025

Introduction

This is the fourth Annual Report of the BLMK APC, and the contents reflect the output from the committee meetings on 1st May 2024, 3rd July 2024, 25th September 2024, 4th December 2024 and 26th February 2025.

At this stage in the report, it is important that we acknowledge the work done by the commitment of committee and subgroup members to making the BLMK APC work effectively.

The BLMK APC is a strategic local decision-making group with responsibility for promoting rational, evidence-based, high quality, cost-effective medicines optimisation across Bedfordshire, Luton and Milton Keynes to ensure equity of access to medicines for all residents.

The APC makes decisions in ways that are clear, consistent and defensible and takes account of regional and national recommendations using an explicit ethical framework and decision-making criteria that clinicians are aware of when submitting applications for clinical support and for funding.

There is a systematic approach to whole therapeutic areas, not looking solely at single medicines in isolation from the care pathway; there will be consideration of other health-system costs to support and facilitate service redesign.

The APC includes Medicines Safety and Antimicrobial Stewardship as standing agenda items.

The APC performs this work on behalf of the BLMK Integrated Care Board (BLMK ICB) and its partnership organisations. The role of the APC includes discussion on BLMK wide implementation of national guidance on the use of medicines, such as NICE Technology Appraisals/Guidelines where medicines are included, assessment of the clinical and cost-effectiveness of medicines and medicines excluded from the NHS Payment Scheme, discussion and agreement of local therapeutic guidelines where there is a large medicines component and assisting in the resolution of problems relating to prescribing at the primary and secondary care interface. The focus of the Committee has changed in recent years. There has been a shift away from evaluation of new medicines to production of therapeutic guidelines/pathways to assist in safe, effective and cost-effective prescribing. This reflects the changing role of Area Prescribing Committees which now focus more on production of medicine related guidelines.

Please [click here](#) to access the current Terms of Reference of BLMK APC. Output from the BLMK APC can be found in [Appendix 1](#).



APC Subgroups

Four subgroups to the APC have been created. All are advisory and make recommendations to the APC for ratification:

1. **BLMK Formulary Subgroup:** There are currently two joint Formularies - Milton Keynes Joint Formulary and Bedfordshire and Luton Joint Formulary. The BLMK Formulary Subgroup focusses on the evaluation of new medicines and additional preparations of existing medicines with potential impact in primary and secondary care (prescribing or commissioning) for addition to both Joint Formularies. It also reviews sections of the Formularies and prepares shared care guidelines. Acute Trust Drugs and Therapeutics Committees focus on reviewing hospital only medicines. Medicines which are the subject of a positive NICE Technology Appraisal Guidance are automatically added to both Joint Formularies. Please [click here](#) to access the current Terms of Reference of the Formulary Subgroup. While formal merger of the two Joint Formularies is not expected in the short term, in the longer term alignment of the Formularies is anticipated as a result of the work of the BLMK Formulary Subgroup.
2. The **BLMK Medicines Safety Group (MSG)** provides information on drug safety updates (DSU) and patient safety alerts to the APC. The MSG is a forum to inform and improve medication safety across the BLMK health economy, sharing of information about and learning from medication safety issues occurring in both primary and secondary care. It also makes medicines safety recommendations which span the interface between primary and secondary care. Please [click here](#) to access the current Terms of Reference of the BLMK Medicines Safety Group.
3. **Wound Management Formulary Steering Group.** The purpose of the Wound Management Formulary Steering Group is to provide strategic oversight in all aspects of Wound Management products across the local health economy in Bedfordshire, Luton and Milton Keynes. To develop, implement, and monitor the application of wound management documentation, policies, guidance and practice. This group has been in existence for many years serving Bedfordshire and Luton and has been extended to include representation from Milton Keynes. Please [click here](#) to access the current Terms of Reference of the Wound Management Formulary Steering Group. Work is ongoing to move towards alignment of the wound care formularies across BLMK, with section reviews being undertaken in addition to consideration of addition or removal of individual products from the formularies. During 2024-25 significant work has been undertaken to align stock supply and ordering processes across BLMK.
4. **Patient Group Direction Subgroup.** The purpose of the Patient Group Direction (PGD) Subgroup is to review and make

recommendations to the APC on patient group directions that the group have agreed are clinically appropriate for use within the commissioned service and meet all the legal requirements. The PGD subgroup ensures that the [ICB PGD policy](#) is applied and that appropriate governance relating to PGD preparation is in place by the organisation preparing the PGD. This is a newer subgroup of the APC which has been operating since May 2023. Please [click here](#) to access the current Terms of Reference of the Patient Group Direction Subgroup.

The APC and its subgroups work to their terms of reference, and follow an Ethical and Commissioning Principles framework, incorporating an Equality and Diversity Impact Assessment where applicable (see [Appendix 2](#)) when producing recommendations on medicines/guidelines. APC and Subgroup members are asked to make an annual declarations of conflict of interest and do not take part in decision-making where a conflict of interest arises.

Participating Organisations

The APC serves the following participating NHS organisations:

- Bedfordshire Hospitals NHS Foundation Trust (Bedford site and Luton & Dunstable site)
- Milton Keynes Hospital University Hospital NHS Foundation Trust
- East London Foundation NHS Trust (ELFT) (Provides Mental Health Services to Bedfordshire and Luton, and Community Health Services to Bedfordshire).
- Cambridgeshire Community Services NHS Trust (Provides Community Health Services to Luton).
- Central and North West London NHS Foundation Trust (CNWL) (Provides Community and Mental Health Services to Milton Keynes).
- Bedfordshire, Luton and Milton Keynes Integrated Care Board

Representation on the APC comes from the participating organisations and is included in the APC Terms of Reference. The Committee chair is a BLMK ICS clinician.

Meeting Attendance Figures

BLMK APC meetings are usually held bi-monthly and the Committee first met in September 2021. There have been a total of five business APC committee meetings held from April 2024 to March 2025. Meetings were held virtually by Microsoft Teams at dates and times that members have said they would be available. Dates and times of meetings are set at least 6 months in advance of the meeting. The table below illustrates APC member and participating NHS organisations' APC attendance from April 2024 to March 2025 for the five business meetings (some members deputise for each other and % attendance reflects this fact). People who attend in an 'in attendance' capacity are not included in the table.

Job Title	Organisation representing	2024/25 % attendance
Chair	Working on behalf of the Committee	100%
Place Based Lead GP– Milton Keynes or Deputy	Place Based Lead GP	80%
Place Based Lead GP – Luton	Place Based Lead GP	40%
Place Based Lead GP – Central Bedfordshire	Place Based Lead GP	100%
Place Based Lead GP – Bedford	Place Based Lead GP	100%
Pharmacist Representative	Bedfordshire Hospitals NHS Foundation Trust	100%
Pharmacist Representative	Milton Keynes University Hospital NHS Foundation Trust	80%
Consultant in Public Health	Working on behalf of the Committee	80%
Medical Representative	Bedfordshire Hospitals NHS Foundation Trust	100%
Medical Representation	Milton Keynes University Hospital NHS Foundation Trust	40%
APC Professional Secretary	Working on behalf of the Committee	100%
Pharmacist Representative	Assisting the Professional Secretary working on behalf of the Committee	100%
Lay Representative	Working on behalf of the Committee	80%
Associate Director: Pharmacy and Medicines optimisation	BLMK ICB	100%
Head of Pharmacy & Medicines Optimisation	BLMK ICB	80%
Lead Pharmacist Excellence & Delivery Manager	BLMK ICB	40%
Medicines Optimisation Lead Pharmacist	BLMK ICB	80%
Chair of Medicines Safety Group	Secondary Care	100%
Chair of Wound Care Group	BLMK ICB	100%
Chair of Formulary Subgroup	BLMK ICB	100%
Formulary Lead Pharmacist	BLMK ICB	100%
Pharmacist Representative	CNWL (Community and Mental Health Services Milton Keynes)	40%
Pharmacist Representative	ELFT (Community Services (Beds)/Mental Health Services (Beds and Luton))	100%
Pharmacist Representative	CCS (Beds & Luton Community Services Provider)	40%
Nurse Representative (Independent Prescriber)	Secondary Care	0%
Practice Pharmacist (Independent Prescriber)*	Primary Care	60%

*New member from September 2024

In addition to those outlined above, the Committee also welcomed the attendance and contribution of other colleagues from participating



organisations, including authors of papers and observers who attended to better understand the work of the Committee.

Committee Activities and Achievements

Communication and consultation

Key stakeholders are identified and consulted when medicines/pathways within specialist areas are discussed. As many views as possible are sought and considered during the APC meeting. Specialists/staff with specialist input are invited to attend APC meetings to contribute to the meeting or make presentations. A total of 31 presentations were made over the five business meetings held from May 2024 to February 2025. In addition, where complex guidelines are discussed, clinicians are invited to participate in subgroup meetings prior to full discussion at APC.

A consensus recommendation is reached by APC members, and these are presented in the form of APC recommendations and more detailed APC guidelines which are communicated to key stakeholders either individually (via email) or through newsletters.

The APC and its subgroups have produced a variety of guidance on the appropriate and cost-effective use of medicines during the 2024/25 financial year and these are outlined below.

Guidelines, Pathways and Bulletins

The following Guidelines, Pathways and Bulletins were produced or updated and ratified during the 2024/25 Financial Year:

- Ophthalmology intravitreal injections algorithm
- Contraception guidance
- Emergency contraception guidance
- Continence appliance prescribing guidelines
- Migraine pathway update
- Atopic dermatitis pathway
- Ulcerative Colitis pathway update
- Iron chelators for myelodysplastic syndrome
- BLMK local lipid guidance
- Antimicrobial guideline update
- Paediatric asthma guidance
- ICS Stepdown for COPD patients
- Self-monitoring of blood glucose (SMBG) for adult patients living with type 2 diabetes
- BLMK Adult Oral Nutritional Supplement Prescribing Guidelines
- BLMK Infant formulae prescribing guidelines
- East of England hypertension protocols (ratified for local use)

Copies of the Guidelines, Pathways and Bulletins are available on the [BLMK Medicines Optimisation website](#) with Formulary specific information available by accessing the two joint formularies:

<http://www.bedsformulary.nhs.uk/>

<https://formularymk.nhs.uk/>

Shared care guidelines/Information for GPs

During 2024/25 the following shared care guidelines (SCGs)/information for GPs were produced or updated and ratified:

- Drospirenone prescribing support information
- Azathioprine/mercaptopurine for Renal Autoimmune Disease shared care guideline
- Mycophenolate mofetil/ Mycophenolic acid for Renal Autoimmune Disease shared care guideline
- Bedfordshire/Luton Azathioprine Rheumatology fact sheet update
- Melatonin Prescribing Support Information – Children & Young People
- Finerenone prescribing support document
- Bempedoic acid prescribing support document
- Inclisiran prescribing support document
- Sucroferric oxyhydroxide (oral) for hyperphosphataemia in adult patients with end stage renal failure requiring renal replacement therapy shared care guideline (Hertfordshire & West Essex document ratified for local use)
- Cinacalcet for Use in Secondary Hyperparathyroidism in Adults with End Stage Kidney Disease (ESKD) Requiring Renal Replacement Therapy shared care guideline (Hertfordshire & West Essex document ratified for local use)
- Sevelamer carbonate (oral) for Hyperphosphataemia in Adult Patients with Chronic Kidney Disease shared care guideline (Hertfordshire & West Essex document ratified for local use)
- Lanthanum (oral) for Hyperphosphataemia in Adult Patients with Chronic Kidney Disease Shared care guideline (Hertfordshire & West Essex document ratified for local use)
- Attention deficit hyperactivity disorder Shared Care Guidance for adults (for patients under the care of ELFT – separate SCG available for patients under the care of Psychiatry UK)
- Apomorphine shared care guideline
- Children and young people ADHD shared care guideline

These are available on the [BLMK Medicines Optimisation Shared Care Guidelines webpage](#) along with previous information.

Miscellaneous Documents

The following miscellaneous documents were approved or noted (for information) by the APC Committee during April 2024 to March 2025:

- BLMK APC Terms of Reference

- BLMK APC annual report 2023/24
- Covid-19 Therapeutics / CMDU updates
- Tirzepatide for managing overweight and obesity updates
- Continuous Glucose Monitoring (CGM) updates
- NHS England clinical policies - gender dysphoria in children and young people
- Risk sharing policy update
- High Flow Oxygen Policy (myAirvo) update
- Safer Valproate prescribing system update
- Minutes of meetings from the contributing organisations to the APC

This information can be found on the [BLMK Medicines Optimisation website](#) and via the Joint Formularies (Formulary specific information):

<http://www.bedsformulary.nhs.uk/>
<https://formularymk.nhs.uk/>

NICE Guidance

NICE Technology Appraisal Guidance (NICE TAs) and guidelines were noted by the BLMK APC from April 2023 to March 2024. NICE TAs which are the commissioning responsibility of ICBs are noted for implementation. NICE Guidelines are noted for information and action where appropriate and NICE TAs where the commissioning responsibility rests with NHS England (NHSE) are noted for information only. As a result of the issue of NICE Guidance, updates to existing APC guidance and BLMK Formulary are undertaken.

See [appendix 3](#) for information on ICB Commissioned NICE Technology Appraisal Guidance considered by the APC between April 2024 and March 2025.

[Click here](#) to access all NICE Guidance issued from 15th February 2024 to 12th February 2025.

Reports received from Subgroups

The APC also received reports from its Subgroups and ratified recommendations made at these groups:

- **BLMK Formulary Subgroup (FSG)**

The Formulary additions and deletions made between April 2024 and March 2025 can be accessed via the Formulary newsletters here: [BLMK ICB All Newsletters](#)

The BLMK Formularies can be accessed by clicking on the following links:

<http://www.bedsformulary.nhs.uk/>
<https://formularymk.nhs.uk/>

- **BLMK Medicines Safety Group (MSG)**

The BLMK Medicines Safety group brought the Drug Safety Updates and national Patient Safety Alerts to the APC for information and action. This information can be accessed from April 2024 to March 2025 APC Newsletters:- [All Newsletters – BLMKICB Medicines Management](#)

- **BLMK Wound Management Formulary Steering Group.**

The APC ratifies the formulary recommendations of the BLMK Wound Care Formulary Steering Group which has representation from relevant clinicians across Bedfordshire, Luton and Milton Keynes. There are community and hospital formularies available, which are available online via the [Wound Management Formulary website](#). The woundcare formularies are also available via the Eolas Medical app.

Details of additions and deletions made to the Wound Care Formulary between April 2024 and March 2025 can be accessed via the APC Newsletters here: [BLMK ICB All Newsletters](#).

- **Patient Group Directions (PGD) Subgroup**

The PGD subgroup makes recommendations to the BLMK APC on approval of PGDs to be used within the BLMK integrated care system. Details of PGDs approved between April 2024 to March 2025 may be found within the relevant [APC meeting notes](#).

- **Antimicrobial Resistance Update**

Updates are provided to the Committee by the BLMK ICB Lead Antimicrobial Pharmacist, and the information provided can be accessed from April 2024 to March 2025 here: [All Newsletters – BLMKICB Medicines Management](#).

A new BLMK antibiotics guidelines website has been developed, which may be accessed here:

[BLMK Antibiotics Live \(blmkantibioticspubliclive.azurewebsites.net\)](https://blmkantibioticspubliclive.azurewebsites.net/)

- **East of England Priorities Advisory Committee (EoE PAC)**

Bulletins produced by the APC have been submitted to the EoE PAC to help inform production of East of England wide policies on medicines where it is appropriate to have these. Outputs from EoE PAC are considered and ratified by the APC as appropriate. There were no relevant PAC bulletins for ratification by the APC in the April 2024 to March 2025 period.

APC Newsletter

An APC Newsletter is produced following each business meeting of the Committee providing a summary of APC recommendations and is widely circulated within the Bedfordshire, Luton and Milton Keynes health economy (Primary care clinicians, Community Pharmacists, and Secondary Care). Five newsletters have been produced between May 2024 and March 2025 and can be accessed from:

<https://medicines.bedfordshirelutonandmiltonkeynes.icb.nhs.uk/all-newsletters/>

Future Work Programme

The work plan of the APC includes updating, aligning and/or developing new pathways/guidelines including the following:

- Vitamin D Pathway Update
- Osteoporosis pathway update



- Chronic kidney disease pathway
- Stoma formulary and fair usage guideline
- Choice of proton pump inhibitors in paediatrics
- COPD guideline update
- Anticoagulant guidelines

Summary

The BLMK Area Prescribing Committee has, during the 2024/25 financial year, continued to build on the legacy of its predecessor committees to ensure the provision of recommendations on the safe, clinical and cost-effective use of medicines to the BLMK ICB and provider Trusts to improve patient outcomes of the Bedfordshire, Luton and Milton Keynes population. The meetings have been well attended with good representation from primary care, secondary care and lay members.

We hope you find this annual report helpful. Any comments on this document are welcomed by the APC Secretary.

APC Secretary contact details:

E-mail: anne.graeff@nhs.net

Priory House

Shefford



Appendix 1: Output from the BLMK Area Prescribing Committee meetings held between April 2024 and March 2025

The approved APC meeting notes can be accessed via the following links:

[1st May 2024](#)

[3rd July 2024](#)

[25th September 2024](#)

[4th December 2024](#)

[26th February 2025](#)


The APC Newsletters (summarising decisions made at the meetings) and Formulary Newsletters (to include agreed updates to the Bedfordshire and Luton Joint Formulary and Milton Keynes Joint Formulary) can be accessed via the following link:

[Newsletters](#)

Appendix 2: Assessment against Ethical and Commissioning Principles

Bedfordshire, Luton and Milton Keynes (BLMK) Area Prescribing Committee (APC)

Assessment against Ethical and Commissioning Principles

Treatment assessed (Month and Year):
APC Recommendation TBC post meeting
1) Clinical Effectiveness <i>e.g. according to national guidelines...</i>
2) Cost Effectiveness <i>e.g. most appropriate and cost- effective products have been recommended</i>
3) Needs of the community <i>e.g. prevalence and incidence of disease being treated?</i>
<p>4) Equity & Equality Impact Assessment (see also embedded additional information including factsheet below to aid completion of this section)</p> <p>Consider whether this decision of the APC will have an impact for patients or staff in regard to Equality, Inclusion and Human Rights legislation. Such impacts (negative) could include:</p> <ul style="list-style-type: none"> • Restriction of a drug which could benefit those with certain conditions^{1,2} <p>Where the implementation of the decision of the BLMK APC may impact on one or more equality group differently to others, a full equality impact assessment may need to be completed as advised by the BLMK Equality and Diversity Lead.</p> <div style="border: 1px solid black; padding: 5px; margin: 10px 0;"> <p>Protected Characteristics (under the Equality Act 2010): Age; Disability; Gender reassignment; Marriage & Civil Partnership (in employment only); Pregnancy & Maternity; Race; Religion & Belief; Sex; Sexual orientation; carers; other identified groups.</p> </div> <div style="text-align: center;">  Equality Impact Assessment Factsheet </div> <p>¹ NB Equality and Diversity is only one part of an assessment of the new drug/indication. ² It should be noted that where the BLMK APC is following national guidance, these have been developed with consultation and are required to have been subject to Equality Analysis and Due Regard.</p>
<p>Please state whether the decision will have an impact:</p> <p>Yes <input type="checkbox"/> <i>If YES, the proposal is likely to impact patients or staff. Please set out those impacts and any mitigations that have been identified in the section below. Examples include a process where the needs of exceptional cases can be met.</i></p> <p>No <input type="checkbox"/> <i>NO, please state that the decision has been reviewed with regard to Equality, Inclusion and Human Rights and no issues have been identified in the section below.</i></p>

Provide rationale for impact assessment: <u><i>Should a significant impact be identified a full EQIA should be completed</i></u>
5) Need for healthcare (incorporates patient choice and exceptional need) <i>e.g. are there alternative therapies available or is this a completely new treatment option?</i>
6) Policy drivers: <i>e.g. relevant local or national guidance</i>
7) Disinvestment: <ul style="list-style-type: none"> <i>• How will this medicine help to address local health priorities?</i> <i>• By using this medicine, what disinvestment in other medicines, interventions and services may be possible?</i> <i>• How much would this save?</i> <i>• Affordability considerations?</i> <i>• Will this medicine help to address local health priorities?</i>
8) Environmental impact of decision (if applicable)

Appendix 3: NICE Technology Appraisal Guidance (ICB Commissioned)

NICE Technology Appraisal Guidance (ICB Commissioned) – considered by BLMK APC April 2024 – March 2025

Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)
Technology appraisal Reference number: TA969 Published: 30 April 2024
<https://www.nice.org.uk/guidance/ta969>

Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 Technology appraisal guidance Reference number: TA971 Published: 08 May 2024
<https://www.nice.org.uk/guidance/ta971>

Atogepant for preventing migraine Technology appraisal guidance Reference number: TA973 Published: 15 May 2024 <https://www.nice.org.uk/guidance/ta973>

Ranibizumab for treating choroidal neovascularisation associated with pathological myopia Technology appraisal guidance Reference number: TA298 Published: 27 November 2013 Last updated: 20 May 2024 <https://www.nice.org.uk/guidance/ta298>

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration Technology appraisal guidance Reference number: TA155 Published: 27 August 2008 Last updated: 20 May 2024 <https://www.nice.org.uk/guidance/ta155>

Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion Technology appraisal guidance Reference number: TA283 Published: 22 May 2013 Last updated: 20 May 2024
<https://www.nice.org.uk/guidance/ta283>

Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over Technology appraisal guidance Reference number: TA986 Published: 10 July 2024 <https://www.nice.org.uk/guidance/ta986>

Tenecteplase for treating acute ischaemic stroke Technology appraisal guidance Reference number: TA990 Published: 24 July 2024
<https://www.nice.org.uk/guidance/ta990>

Abaloparatide for treating osteoporosis after menopause Technology appraisal guidance Reference number: TA991 Published: 07 August 2024
<https://www.nice.org.uk/guidance/ta991>

Linzagolix for treating moderate to severe symptoms of uterine fibroids Technology appraisal guidance Reference number: TA996 Published: 14 August 2024
<https://www.nice.org.uk/guidance/ta996>

Relugolix for treating hormone-sensitive prostate cancer Technology appraisal guidance Reference number: TA995 Published: 14 August 2024
<https://www.nice.org.uk/guidance/ta995>

Risankizumab for treating moderately to severely active ulcerative colitis Technology appraisal guidance Reference number: TA998 Published: 22 August 2024
<https://www.nice.org.uk/guidance/ta998>

Vibegron for treating symptoms of overactive bladder syndrome Technology appraisal guidance Reference number: TA999 Published: 04 September 2024
<https://www.nice.org.uk/guidance/ta999>

Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion Technology appraisal guidance Reference number: TA1004 Published: 11 September 2024 <https://www.nice.org.uk/guidance/ta1004>

Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) Technology appraisal Reference number: TA1006 Published: 12 September 2024 <https://www.nice.org.uk/guidance/ta1006>

Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension Technology appraisal guidance Reference number: TA1009 Published: 02 October 2024 <https://www.nice.org.uk/guidance/ta1009>

Bevacizumab gamma for treating wet age-related macular degeneration Technology appraisal guidance Reference number: TA1022 Published: 04 December 2024
<https://www.nice.org.uk/guidance/ta1022>

Tirzepatide for managing overweight and obesity Technology appraisal guidance Reference number: TA1026 Published: 23 December 2024
<https://www.nice.org.uk/guidance/ta1026>

Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban Technology appraisal guidance Reference number: TA697 Published: 12 May 2021 Last updated: 15 January 2025 <https://www.nice.org.uk/guidance/ta697>

Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) Technology appraisal Reference number: TA1029. Published: 15 January 2025 <https://www.nice.org.uk/guidance/ta1029>

12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites Technology appraisal guidance Reference number: TA1045 Published: 05 March 2025 <https://www.nice.org.uk/guidance/ta1045>